{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:13:00Z","timestamp":1740136380128,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10072-021-05097-2","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T14:03:32Z","timestamp":1612361012000},"page":"1661-1664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide"],"prefix":"10.1007","volume":"42","author":[{"given":"Mehmet Fatih","family":"Yetkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Aleyna","family":"Yetkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-3602","authenticated-orcid":false,"given":"Merve","family":"Akcakoyunlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meral","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"issue":"5","key":"5097_CR1","doi-asserted-by":"publisher","first-page":"105955","DOI":"10.1016\/j.ijantimicag.2020.105955","volume":"55","author":"P Zhai","year":"2020","unstructured":"Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y (2020) The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 55(5):105955","journal-title":"Int J Antimicrob Agents"},{"key":"5097_CR2","doi-asserted-by":"publisher","first-page":"116832","DOI":"10.1016\/j.jns.2020.116832","volume":"413","author":"AA Asadi-Pooya","year":"2020","unstructured":"Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 413:116832","journal-title":"J Neurol Sci"},{"key":"5097_CR3","doi-asserted-by":"publisher","first-page":"105921","DOI":"10.1016\/j.clineuro.2020.105921","volume":"194","author":"V Montalvan","year":"2020","unstructured":"Montalvan V, Lee J, Bueso T, de Toledo J, Rivas K (2020) Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg 194:105921","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"5097_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1136\/jnnp-2020-323414","volume":"91","author":"H Manji","year":"2020","unstructured":"Manji H, Carr AS, Brownlee WJ, Lunn MP (2020) Neurology in the time of COVID-19. J Neurol Neurosurg Psychiatry 91(6):568\u2013570","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"5097_CR5","first-page":"324","volume":"26","author":"A Sepehrinezhad","year":"2020","unstructured":"Sepehrinezhad A, Shahbazi A, Negah SS (2020) COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. J Neuro-Oncol 26(3):324\u2013329","journal-title":"J Neuro-Oncol"},{"key":"5097_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jaut.2014.01.022","volume":"48-49","author":"D Karussis","year":"2014","unstructured":"Karussis D (2014) The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun 48-49:134\u2013142","journal-title":"J Autoimmun"},{"key":"5097_CR7","doi-asserted-by":"crossref","unstructured":"Maghzi AH et al (2020) COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol:1\u20137","DOI":"10.1007\/s00415-020-09944-8"},{"issue":"2","key":"5097_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintor\u00e9 M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"issue":"13","key":"5097_CR9","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1177\/1352458519881950","volume":"26","author":"A Jain","year":"2020","unstructured":"Jain A, Rosso M, Santoro JD (2020) Wilhelm Uhthoff and Uhthoff\u2019s phenomenon. Mult Scler 26(13):1790\u20131796","journal-title":"Mult Scler"},{"issue":"3\u20134","key":"5097_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000361045","volume":"72","author":"K Park","year":"2014","unstructured":"Park K, Tanaka K, Tanaka M (2014) Uhthoff\u2019s phenomenon in multiple sclerosis and neuromyelitis optica. Eur Neurol 72(3\u20134):153\u2013156","journal-title":"Eur Neurol"},{"issue":"23","key":"5097_CR11","doi-asserted-by":"publisher","first-page":"e2468","DOI":"10.1212\/WNL.0000000000009504","volume":"94","author":"JB Davion","year":"2020","unstructured":"Davion JB, Lopes R, Drumez \u00c9, Labreuche J, Hadhoum N, Lannoy J, Vermersch P, Pruvo JP, Leclerc X, Z\u00e9phir H, Outteryck O (2020) Asymptomatic optic nerve lesions: an underestimated cause of silent retinal atrophy in MS. Neurology 94(23):e2468\u2013e2478","journal-title":"Neurology"},{"issue":"6","key":"5097_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/brainsci10060345","volume":"10","author":"MK Boziki","year":"2020","unstructured":"Boziki MK, Mentis AA, Shumilina M, Makshakov G, Evdoshenko E, Grigoriadis N (2020) COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. Brain Sci 10(6):345","journal-title":"Brain Sci"},{"issue":"4","key":"5097_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000382130","volume":"44","author":"T Kalincik","year":"2015","unstructured":"Kalincik T (2015) Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology 44(4):199\u2013214","journal-title":"Neuroepidemiology"},{"key":"5097_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2147\/TCRM.S257714","volume":"16","author":"SM Hamdy","year":"2020","unstructured":"Hamdy SM, Abdel-Naseer M, Shehata HS, Hassan A, Elmazny A, Shalaby NM, Abokrysha NT, Kishk NA, Nada MAF, Ahmed SM, Hegazy MI, Mekkawy D, Mourad HS, Abdelalim A, Berger T (2020) Managing disease-modifying therapies and breakthrough activity in multiple sclerosis patients during the COVID-19 pandemic: toward an optimized approach. Ther Clin Risk Manag 16:651\u2013662","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"5097_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","volume":"74","author":"A Bar-Or","year":"2014","unstructured":"Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H (2014) Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74(6):659\u2013674","journal-title":"Drugs"},{"issue":"9","key":"5097_CR16","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1177\/1352458519851981","volume":"26","author":"G Comi","year":"2020","unstructured":"Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS (2020) Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: pooled analysis of clinical trials. Mult Scler 26(9):1083\u20131092","journal-title":"Mult Scler"},{"key":"5097_CR17","doi-asserted-by":"publisher","unstructured":"Mantero V, Baroncini D, Balgera R, Guaschino C, Basilico P, Annovazzi P, Zaffaroni M, Salmaggi A, Cordano C. Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10196-9","DOI":"10.1007\/s00415-020-10196-9"},{"key":"5097_CR18","unstructured":"M\u00f6hn N et al (2020) Mild COVID-19 symptoms despite treatment with teriflunomide and hi3gh-dose methylprednisolone due to multiple sclerosis relapse. J Neurol 1\u20133"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05097-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05097-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05097-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T15:07:36Z","timestamp":1671030456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05097-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5097"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05097-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"20 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval is not applicable. A written informed consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"There is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}